FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.
What happened
FDA inspected Dr. Jeffries’ clinical site in Houston from July 19 to August 5, 2021, as part of its Bioresearch Monitoring Program. The agency found that she conducted Protocol ANES001 with diazepam, tramadol, ondansetron, and MKO Melt without an IND in effect and did not meet the exemption criteria. FDA also found informed-consent failures: subjects were not given a copy of the consent form, and the form did not identify experimental procedures or describe reasonably foreseeable risks.
What FDA found
The investigator began and ran a clinical trial of diazepam, tramadol, ondansetron, and MKO Melt without submitting and having an IND in effect.
21 CFR 312.20(a), 312.20(b), 312.40(a)The trial did not qualify for the IND exemption because it gave tramadol and diazepam to cataract-surgery patients at a dose and in a combination that significantly increased risks.
21 CFR 312.2(b)(1)(iii)The investigator did not give subjects a copy of the informed consent form.
21 CFR 50.27(a)The informed consent form did not identify experimental procedures or describe reasonably foreseeable risks.
21 CFR 50.25(a)(1), (2)
What FDA wants
Within 15 business days of receipt, notify CDER’s Office of Scientific Investigations in writing of actions taken to prevent similar violations. If the investigator believes she complied, include reasoning and supporting information.
Who should pay attention
- clinical investigators and sponsors running drug trials
- IRBs and research sites
- anesthesia and cataract surgery practices conducting research
This is a summary. Read the original letter on fda.gov.